Big congratulations to A/Prof. John Wentworth who received the Australian Diabetes Society Ranji and Amara Wikramanayake Clinical Diabetes Research Award. This award recognises significant contributions to diabetes research by a mid-career clinician. A/Prof Wentworth leads or co-leads various JDRF-funded projects including Type1Screen and the Australasian Type 1 Diabetes Immunotherapy Collaborative (ATIC), a key platform driving immunotherapy clinical trials for type 1 diabetes in Australia. St Vincent's Institute of Medical Research The Royal Melbourne Hospital
JDRF Australia
Research
St Leonards, NSW 3,649 followers
Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications.
About us
JDRF is the world’s leading not-for-profit supporter of type 1 diabetes research, investing more than $1.6 billion since 1970, including more than $63 million into Australian research. JDRF’s support has been behind most major advances in type 1 diabetes research in the past four decades. We collaborate with industry partners, commercial partners and governments to bring our research results into the lives of people living with type 1 diabetes. As we work towards a cure, we also support the type 1 diabetes community with advocacy, resources and personal connection.
- Website
-
http://www.jdrf.org.au
External link for JDRF Australia
- Industry
- Research
- Company size
- 11-50 employees
- Headquarters
- St Leonards, NSW
- Type
- Nonprofit
- Founded
- 1982
- Specialties
- Funding, Advocacy, Type 1 diabetes, Not for profit , Community support, Research strategy, and Medical research
Locations
-
Primary
Level 4, 80 Chandos St
St Leonards, NSW 2070, AU
Employees at JDRF Australia
Updates
-
Smart insulin could be on the horizon thanks to a $750,000 funding injection for Professor Christoph Hagemeyer. Prof Hagemeyer and his team at Monash University are developing a ‘glucose responsive insulin’ formulation, which aims to mimic a healthy pancreas more closely. This insulin formulation is designed to release insulin only when glucose levels are high and become inactive when glucose levels drop. This could take the burden out of insulin calculations and dosing, reduce the frequency of insulin injections, and reduce the risk of complications associated with type 1 diabetes. The funding was committed from the Type 1 Diabetes Grand Challenge, a partnership between JDRF UK, Diabetes UK, and Steve Morgan Foundation.
-
Research holds the key to unlock a world without type 1 diabetes (T1D). This includes prevention research, so that one day no person will receive a T1D diagnosis. Our amazing advocate, Giselle, recently spoke to Dr Kirstie Bell about her leading prevention research and her hopes for a T1D screening program. With $50 million from the Government, our Clinical Research Network (CRN) could keep funding research just like this and help us reach our goals. #ReserachHoldsTheKey 🔑
-
Congratulations to Dr Jennifer Snaith who has been awarded the 2024 Australian Diabetes Society Lindsey Baudinet Rising Star Award in Type 1 Diabetes Research. This award supports exceptional early-career researchers to pursue research in type 1 diabetes (T1D) and its complications. Dr Snaith is being supported through JDRF’s Rebecca Davies Clinician Research Fellowship, which allows clinicians the opportunity to undertake T1D research alongside their clinical work. Dr Snaith is a Sydney-based endocrinologist who is researching insulin resistance, new therapies and cardiovascular health in T1D through the Garvan Institute of Medical Research. Australian Diabetes Society
-
We have an exciting opportunity in our VIC/TAS office for an experienced Development Manager with excellent leadership skills, who can drive engagement and build strong relationships across multiple sectors, including the type 1 diabetes community, donors and the corporate sector. For further information or to apply visit the SEEK link below.
-
JDRF is at the Australasian Diabetes Congress in Perth! Come and say hi to the team, check out our packs for newly diagnosed kids and adults, and learn about our upcoming mental health program and transition pilot program for teens - and lots more! #ADC2024
-
Smart insulin could be on the horizon thanks to a $750,000 funding injection for Professor Christoph Hagemeyer. Prof Hagemeyer and his team at Monash University are developing a ‘glucose responsive insulin’ formulation, which aims to mimic a healthy pancreas more closely. This insulin formulation is designed to release insulin only when glucose levels are high and become inactive when glucose levels drop. The funding was committed from the Type 1 Diabetes Grand Challenge, a partnership between JDRF UK, Diabetes UK, Steve Morgan Foundation. 🔬💡
-
Research holds the key for: 🔑Preventions for type 1 diabetes (T1D) 🔑Precision medicine for the community 🔑Progress, to take us closer to a cure for T1D $50 million from the Government could make that a reality and move us closer to a world without T1D. Learn more about our ask on our website. #ResearchHoldsTheKey #Type1Diabetes
-
Exciting type 1 diabetes (T1D) research news this morning, with six smart insulin projects funded by the Type 1 Diabetes Grand Challenge. Glucose-responsive, or ‘smart insulins’, are designed to mimic the natural action of the pancreas and respond to blood glucose levels in real time. The Type 1 Diabetes Grand Challenge is a partnership between JDRF UK, Diabetes UK, and Steve Morgan Foundation. The funded projects include one headed up by Professor Christoph Hagemeyer, from Australia’s Monash University. New insulin formulations represent real hope for transforming T1D management.
Scientists hail ‘smart’ insulin that responds to changing blood sugar levels in real time
theguardian.com